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Abstract 
Purpose: To report a case of Coats’ disease managed with the dexamethasone intravitreal 
implant Ozurdex® (Allergan, Inc., Irvine, Calif., USA) combined with retinal photocoagulation.  
Methods: A 46-year-old female with 20/200 visual acuity was diagnosed with Coats’ disease 
with secondary retinal vasoproliferative tumor. An initial approach was performed with an 
intravitreal injection of the sustained-release dexamethasone implant Ozurdex. After 
reattachment of the retina, the telangiectatic vessels were treated with laser 
photocoagulation.  
Results: The patient’s visual acuity improved to 20/25 after the intravitreal Ozurdex. No 
further recurrences of exudation were evident through the 12-month follow-up.  
Conclusions: Ozurdex may be an effective initial therapeutic approach for Coats’ disease 
with immediate anatomical response and visual improvement. 
 
Introduction 
Coats’ disease is a unilateral, idiopathic retinal vascular abnormality characterized 
by telangiectatic retinal vessels in association with lipid exudation [1]. Although most 
cases are diagnosed before the age of 20 years, Coats’ disease may also be diagnosed in  
Case Rep Ophthalmol 2012;3:123–127 
DOI: 10.1159/000337481 
Published online: 
March 26, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1663–2699 
www.karger.com/cop 
 
 
 
124 
adult patients [2]. Current therapeutic strategies include observation, ablation of 
abnormal retinal telangiectasis by photocoagulation – or cryotherapy – and surgery for 
retinal detachment. Recent publications regarding the off-label use of triamcinolone [3, 
4] or vascular endothelial growth factor inhibitors [5–7] have been published with 
inconclusive outcomes, requiring several rounds of retreatment in most cases. The 
purpose of any treatment for Coats’ disease is to establish a prompt and long-standing 
visual recovery, with the safest profile for patients. 
Case Report 
A 46-year-old female was referred to our department with a 3-week history of progressive vision 
loss in her left eye. The best corrected visual acuity (BCVA) was 20/20 in her right eye and 20/200 in 
her left eye. Anterior segment examination was unremarkable. 
Whereas the right eye fundus did not show any significant change, in the left eye massive 
exudation within the inferior-temporal quadrant of the retina was evident, with posterior pole 
involvement and intraretinal lipid accumulation. In addition, a grayish mass was observed in the 
inferior peripheral retina (fig. 1). Spectral-domain optical coherence tomography (SD-OCT) 
confirmed the presence of exudative retinal detachment with macular involvement (fig. 1). Numerous 
hyperreflective intraretinal lesions corresponding to lipids were evident. An echography showed an 
intraretinal mass (4.1 × 1.9 mm) located in the inferior periphery, associated with the exudative 
retinal detachment (fig. 1). Fluorescein angiography (fig. 1) revealed the presence of telangiectatic 
vessels scattered all over the inferior-temporal retinal quadrant; the peripheral inferior mass was 
identified as a retinal vasoproliferative tumor (RVT) with clearly defined afferent and efferent vessels. 
With the presumptive diagnosis of Coats’ disease with exudative inferior-temporal retinal 
detachment and secondary RVT, the patient was treated with an intravitreal injection of the 
sustained-release dexamethasone implant Ozurdex® (Allergan, Inc., Irvine, Calif., USA). One week 
later, her BCVA improved to 20/40 and SD-OCT revealed a complete resolution of the exudative 
retinal detachment (fig. 2). The telangiectatic vessels were treated with laser photocoagulation 
guided by fluorescein angiography in 3 consecutive sessions with 15-day intervals. The volume of the 
RVT decreased progressively until complete retinographic and echographic disappearance. 
Through the follow-up, no further recurrences of the exudative retinal detachment were found, 
and the extensive lipid exudation progressively regressed. One year after initial treatment with 
intravitreal Ozurdex, the patient’s BCVA was 20/25 (fig. 3). 
Discussion 
The pathogenesis of Coats’ disease includes impairment of the blood-retinal barrier 
resulting in both intraretinal and subretinal fluid, and blood and lipid accumulation. In 
addition, weakening of the retinal vessel walls leads to the formation of telangiectasis, 
aneurysms and progressive leakage, resulting in exudative retinal detachment [8]. One 
of the possible complications of Coats’ disease is the development of secondary RVT [9], 
as evidenced in our patient’s case. 
Intravitreal injection of dexamethasone has been shown to attenuate leukostasis and 
vascular leakage [10]. This fact may be of great help in the management of Coats’ 
disease, given the underlying inflammatory component [11]. Ozurdex is a novel, 
biodegradable, sustained-release dexamethasone delivery system approved for the 
treatment of macular edema following retinal vein occlusion [12]. Recently published 
clinical trials expand the efficacy of Ozurdex to the management of diabetic macular 
edema [13] and uveitic macular edema [14].  
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In our patient’s case, a single injection of Ozurdex was able to dramatically improve 
visual acuity and resolve the exudative retinal detachment. Further photocoagulation 
may lead to closure of telangiectasis; no further recurrence of exudation was seen 
through a 12-month follow-up. Further studies are warranted in order to confirm the 
high efficacy of Ozurdex in the initial management of Coats’ disease. 
 
 
 
 
 
 
Fig. 1. a Retinography of the left eye reveals massive exudation within the inferior-temporal quadrant 
of the retina. b Horizontal and vertical (c) OCT scans (indicated as B and C, respectively, in a) centered 
in the fovea confirm the presence of exudative retinal detachment with macular involvement. 
d Fluorescein angiography shows the presence of telangiectatic vessels scattered all over the inferior-
temporal retinal quadrant. 
 
 
 
Fig. 2. a Retinography shows the presence of the Ozurdex® device 1 week after its implantation. 
b Horizontal OCT scan and 3-dimensional reconstruction (c) show the presence of the implant 
adjacent to the retinal vasoproliferative tumor. 
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Fig. 3. Retinography after 12 months of follow-up reveals regression of lipid exudation and retinal 
scars from photocoagulation. 
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